Topical Antifungal Drug Products for Over-the-Counter Human Use; Proposed Amendment of Final Monograph

Riepilogo

The Food and Drug Administration (FDA) is issuing a notice of proposed rulemaking that would amend the final monograph for over-the- counter (OTC) topical antifungal drug products. The amendment makes a minor change in the indications for these drug products. This proposal is part of the ongoing review of OTC drug products conducted by FDA.